THU0649 PHENOTYPIC CLUSTERS OF RHEUMATIC/SYSTEMIC IMMUNE-RELATED ADVERSE EVENTS INDUCED BY CANCER IMMUNOTHERAPIES (IMMUNOCANCER INTERNATIONAL REGISTRY)

Abstract

Background: The ImmunoCancer International Registry is a Big Data-Sharing multidisciplinary network focused on the research of the immune-related adverse events (irAEs) related to cancer immunotherapies (CIs). Objectives: To analyse the worldwide scenario of rheumatic/systemic autoimmune diseases (RSirAEs) associated with the use of CIs during the last 20 years. Methods: The first objective was to develop a systematic literature review crossing the CIs terms with rheumatic and systemic autoimmune diseases using MedDRAVR 15.0 terms. Results: RSirAEs were identified in 11% of 12648 patients with irAEs, including 1435 cases (30% fulfilled criteria for a systemic disease) that were classified in 5 phenotypic clusters: Non-characterized cases included myositis (25%), arthritis (12%), arthral-gias (8%), sicca syndrome (7%) and vasculitis (6%); sarcoidosis (6%), myasthenia gravis (5%), polymyalgia rheumatica (4%), leukocytoclastic vasculitis (3%) and giant cell arteritis (2%) were the most frequent systemic diseases identified: In comparison with patients with organ-specific irAEs, RSirAEs were more frequently associated with combined therapies (OR 2.46, CI 2.16-2.81), checkpoint inhibitors-ICis-(OR 4.01 vs TKis, CI 3.26-4.92), and PD-1is (OR 2.46 vs CTLA4is, CI95% 2.16-2.81) Conclusion: Rheumatic/systemic irAEs can be divided into 5 phenotypic clusters: articular, muscular, granulomatous, vasculitic and systemic. These findings must be confirmed in real-life patients, and an international data-sharing ICIR registry is planned to be launched.